Accuray to be Acquired by Health Catalyst Capital for $1.1B

Ticker: ARAY · Form: 8-K · Filed: Aug 13, 2025 · CIK: 1138723

Sentiment: bullish

Topics: acquisition, merger, healthcare

Related Tickers: ARAY

TL;DR

Accuray is being bought for $1.1B ($22/share cash deal) by Health Catalyst Capital.

AI Summary

Accuray Incorporated announced on August 13, 2025, that it has entered into a definitive agreement to be acquired by a subsidiary of Health Catalyst Capital Management, LLC. The transaction is valued at approximately $1.1 billion, with shareholders set to receive $22.00 in cash for each share of common stock they own. This acquisition marks a significant event for Accuray, a provider of radiation oncology systems.

Why It Matters

This acquisition by Health Catalyst Capital at a significant premium indicates a belief in Accuray's future value and could lead to strategic changes in the radiation oncology market.

Risk Assessment

Risk Level: medium — The deal is definitive, but regulatory approvals and closing conditions introduce some risk before the transaction is finalized.

Key Numbers

Key Players & Entities

FAQ

What is the total value of the acquisition agreement?

The definitive agreement values Accuray Incorporated at approximately $1.1 billion.

What is the price per share for Accuray stockholders?

Accuray shareholders will receive $22.00 in cash for each share of common stock they own.

Who is acquiring Accuray Incorporated?

Accuray Incorporated is being acquired by a subsidiary of Health Catalyst Capital Management, LLC.

When was the earliest event reported in this filing?

The earliest event reported in this Form 8-K filing is dated August 13, 2025.

What is Accuray's primary business?

Accuray Incorporated is a provider of radiation oncology systems.

Filing Stats: 800 words · 3 min read · ~3 pages · Grade level 11.4 · Accepted 2025-08-13 16:05:11

Key Financial Figures

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On August 13, 2025, Accuray Incorporated (the "Company") issued a press release announcing its financial results for the fourth quarter and fiscal year ended June 30, 2025. A copy of the Company's press release dated August 13, 2025, titled "Accuray Reports Fourth Quarter and Fiscal 2025 Financial Results" is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information (including the exhibit hereto) is being furnished under "Item 2.02 Results of Operations and Financial Condition" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), except as shall be expressly set forth by specific reference in such filing.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. Spokespersons of the Company plan to present the information in the presentation attached hereto as Exhibit 99.2 to analysts and investors from time to time on or after August 13, 2025. The presentation will be available on the Company's Investor Relations website at: http://investors.accuray.com. The furnishing of the attached presentation is not an admission as to the materiality of any information therein. The information contained in the presentation is summary information that is intended to be considered in the context of more complete information included in the Company's filings with the U.S. Securities and Exchange Commission and other public announcements that the Company has made and may make from time to time by press release or otherwise. The Company undertakes no duty or obligation to update or revise the information contained in this report. For important information about forward looking statements, see the slide titled "Forward-Looking Statements" in Exhibit 99.2 attached hereto. The information set forth under Item 2.02 of this Current Report on Form 8-K is incorporated by reference into this Item 7.01. The information contained in this Item 7.01 disclosure, including Exhibit 99.1 and Exhibit 99.2, is furnished pursuant to Item 7.01 and shall not be deemed to be "filed" for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into a filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release dated August 13, 2025, titled "Accuray Reports Fourth Quarter and Fiscal 2025 Financial Results" 99.2 Accuray Fourth Quarter and Fiscal 2025 Earnings Call Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ACCURAY INCORPORATED Date August 13, 2025 By: /s/ Ali Pervaiz Ali Pervaiz Senior Vice President & Chief Financial Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing